First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.
APA
Yoshida Y, Yokouchi H, et al. (2025). First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.. Clinical lung cancer, 26(8), e688-e692. https://doi.org/10.1016/j.cllc.2025.08.005
MLA
Yoshida Y, et al.. "First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.." Clinical lung cancer, vol. 26, no. 8, 2025, pp. e688-e692.
PMID
40903386
같은 제1저자의 인용 많은 논문 (5)
- PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters.
- Partial Response to Repotrectinib in ROS1-Rearranged Lung Squamous Cell Carcinoma: A Brief Report.
- Two Cases of Resected Solitary Pulmonary Capillary Hemangioma with Ground-glass Attenuation on CT Imaging.
- A Case of Sigmoid Colon Cancer with Patent Foramen Ovale and Left-Sided Inferior Vena Cava Initially Detected during the Workup for Cerebral Infarction.
- A case of idiopathic gynecomastia treated by endoscopic reduction mammoplasty.